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Abstract
Background: DNA polymerase beta (pol beta), the error-prone DNA polymerase of single-
stranded DNA break repair as well as base excision repair pathways, is overexpressed in several
tumors and takes part in chemotherapeutic agent resistance, like that of cisplatin, through
translesion synthesis. For this reason pol beta has become a therapeutic target. Several inhibitors
have been identified, but none of them presents a sufficient affinity and specificity to become a drug.
The fragment-based inhibitor design allows an important improvement in affinity of small
molecules. The initial and critical step for setting up the fragment-based strategy consists in the
identification and structural characterization of the first fragment bound to the target.
Results: We have performed docking studies of pamoic acid, a 9 micromolar pol beta inhibitor,
and found that it binds in a single pocket at the surface of the 8 kDa domain of pol beta. However,
docking studies provided five possible conformations for pamoic acid in this site. NMR experiments
were performed on the complex to select a single conformation among the five retained. Chemical
Shift Mapping data confirmed pamoic acid binding site found by docking while NOESY and
saturation transfer experiments provided distances between pairs of protons from the pamoic acid
and those of the 8 kDa domain that allowed the identification of the correct conformation.
Conclusion: Combining NMR experiments on the complex with docking results allowed us to
build a three-dimensional structural model. This model serves as the starting point for further
structural studies aimed at improving the affinity of pamoic acid for binding to DNA polymerase
beta.
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DNA polymerase β (pol beta) is the smallest human DNA
polymerase and the first discovered adaptative polymer-
ase. The structure of the full-length protein of 39 kDa has
been solved by X ray cristallography [1]. It is divided into
two structural subdomains, which have distinct functions.
The first is termed the 8 kDa domain and is located at the
N-terminal position. It binds to single-stranded and dou-
ble stranded DNA, recognizes the 5'-phosphate group in
gapped DNA and possesses dRP lyase activity [2]. The sec-
ond, the C-terminal 31 kDa domain, displays the catalytic
activity of polymerisation [3].
Pol beta is the major enzyme of the single-stranded break
DNA repair and base excision repair pathways [4-6]. It is
able to remove damaged base residues, nucleotides and
abasic sites arising from various endogenous and exoge-
nous sources [7]. Thereby, when pol beta gene is deleted
from mouse fibroblasts, hypersensitivity to monofunc-
tional alkylation agents, e.g., methylmethanesulfonate, is
observed [8,9]. Furthermore, pol beta is able to bypass
DNA lesions which block the replication by the replicative
DNA polymerases. In fact, pol beta allows an error-prone
translesion replication of some adducts, like those gener-
ated by cisplatin [10-13]. A large and readily adaptable
binding site and a lack of 3'-5'-exonuclease activity facili-
tates synthesis through lesions. Hence, pol beta seems to
be involved in chemotherapeutic agent resistance, as its
overexpression diminishes the efficacy of anticancer drug
therapies using cisplatin [14]. Indeed, in breast, colon and
prostate tumors, a cisplatin resistance is often observed
while pol beta is overexpressed [15].
Since it causes genetic instability and resistance to antican-
cer drugs, pol beta is a therapeutic target. Within the last
few years, there has been considerable effort to find inhib-
itors of pol beta with higher affinity and greater specificity
[16-18].
Among the approaches that aim at conceiving inhibitors,
the fragment-based drug design is a recent one, that has
proven to be successful [19]. Briefly, in this approach, two
weakly binding ligands or fragments of the target are
sought so that they can be covalently bound to obtain a
final molecule, whose affinity is roughly the product of
individual affinities of the two fragments [20].
To use this approach, sizeable structural information is
required, in particular orientation and conformation of
both fragments in their respective sites on the target. This
information, together with the distance between frag-
ments, is used to define a linker capable of connecting
both fragments without disrupting the global affinity.
Nuclear Magnetic Resonance (NMR) spectroscopy is a
very powerful structural technique in the fragment-based
strategy, as it can detect weakly interacting fragments and
provide distances between target and ligand protons and
structural information on the interaction. In the context of
searching a pol beta inhibitor, we concentrated our efforts
on the 8 kDa domain, defined by a protease sensitive
hinge region at Lys87. Its structure has been solved by
NMR [21,22]. It is formed by 4 alpha helices, packed as
two antiparallel pairs. The helices 1 (from Gly13 to Val
29) and 2 (from Ile33 to Lys48) are linked by a 4 amino-
acid loop. A "helix-hairpin-helix" motif links helix 3
(from Ser55 to Lys61) to helix 4 (from Thr67 to Thr79),
which is responsible for non-specific DNA binding
[23,24]. The alpha helix from Arg83 to Gln90 formed in
the full-length protein is not folded in the 8 kDa domain.
The first step of polymerisation process by pol beta
involves the 8 kDa domain. Moreover, the alkylation-sen-
sitive phenotype can be rescued by expression of the 8
kDa domain, suggesting that removal of the dRP group is
most critical during base excision repair [25].
Among the large number of pol beta inhibitors that have
been reported so far, the pamoic acid binds to the 8 kDa
domain with a reasonable affinity [26]. Its solubility in
aqueous buffer makes it interesting for further NMR anal-
ysis. Moreover, the presence of hydroxyl and carboxyl
groups allows simple chemical modifications, aiming at
tethering other fragments.
This paper describes structural data obtained on the com-
plex of pamoic acid with the 8 kDa domain. A combina-
tion of computational approaches and experimental data
obtained from NMR provided the exact orientation of
pamoic acid bound to the 8 kDa domain, allowing to pro-
pose a three-dimensional model of the complex. We
found that pamoic acid binds to a site formed by helix 2
and helix 4, which also corresponds to the single-stranded
DNA binding site. The conformation of the bound pam-
oic acid affords possible binding of a second fragment in
its vicinity. The current work is the starting point to apply
the fragment-based strategy, that is to say identifying a sec-
ond fragment that binds in the vicinity of the pamoic acid
site.
Results and Discussion
Docking pamoic acid to the 8 kDa domain
We used AutoDock 3.0.5 [27] to dock pamoic acid to the
8 kDa domain of pol beta (PDB code 1DK3). Structures
generated by AutoDock have been ranked according to
their binding energy with the protein and 100 lowest
energy structures were retained for further analysis. With
the force field used by AutoDock, the energy values for the
best ligands varied from -9.58 kcal/mol to -8.96 kcal/mol.
Systematic analysis of the 100 best docked structures
revealed that all of them were located in a single site,Page 2 of 12
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domain during docking. Close atomic contacts between
pairs of protein-ligand atoms, with a distance cutoff of 2
Angströms, were computed. Nine residues, namely His34,
Lys35, Asn37, Ala38, Lys41 on helix 2 and Gly64, Gly66,
Lys68, Lys69 on helix 4, were frequently found to be close
to pamoic acid. In fact, in more than 50% of the resulting
conformations, at least one proton of Ala38, Lys68 and
Ile69 was located within 2 Å from pamoic acid. For resi-
dues His34, Lys35, Asn37, Lys41, Gly64 and Gly66, over
20% of the 100 best docked structures contained a pair of
protein-ligand atoms with a separation below 2 Å. Map-
ping these residues onto the 8 kDa domain structure indi-
cated that they form a single positively charged groove at
the surface of the 8 kDa domain (Fig. 1). Interestingly,
Lys35, Lys60 and Lys68, which have been shown to be
responsible for single-stranded DNA binding by site-
directed mutagenesis [28], are located in the groove where
pamoic acid binds to. As this groove is the one where DNA
binds, pamoic acid is likely to interfere with single-
stranded DNA recognition. Clustering the 100 best ligand
structures has been performed using an RMSD (Root
Mean Square Deviation) cutoff value of 2 Å. The five
resulting clusters indicated that the ligands adopt five dif-
ferent ensembles of conformations in the binding site
described above (Fig. 2). Two conformations, n°2 and
n°3, were closer to each other than to any other one. The
minimum RMSD value between these two conformations
Mapping residues found close to pamoic acid by docking experiments on the structure of the 8 kDa domainFigure 1
Mapping residues found close to pamoic acid by docking experiments on the structure of the 8 kDa domain. 
Ribbon view of the 3D structure of the 8 kDa domain (PDB code 1DK3), highlighting residues found to be involved in binding 
with pamoic acid from docking experiments (colored in magenta). The four alpha helices and the "HhH" motif are annotated. 
Picture was prepared with PyMOL [48].Page 3 of 12
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value with respect to other conformations, from 7.03 Å
with conformation n°1 to 8.12 Å with conformation n°4.
RMSD values between others pairs of clusters were
between 4.5 Å and 6.5 Å.
Two other sites can be defined in the proximity of the
pamoic binding site. The first site could be located further
beyond Lys35, between helices 1 and 4 and neighboring
Leu19, Leu22, Glu26 or Lys72. The other potential site
could be related to Lys60, Leu62 and Ala70, further in the
direction of Gly64 and Gly66, which belong to pamoic
acid site. Since we intend to modify one of the carboxyl
groups of pamoic acid to tether a second fragment to
reach one of the other two sites, the precise orientation of
pamoic acid in the binding site has to be determined.
Chemical Shift Mapping confirms the pamoic acid binding 
site found by docking
In order to discriminate between the five different confor-
mations, binding of pamoic acid to the 8 kDa domain of
pol beta was probed using NMR chemical shift mapping
[29] (Fig. 3). This technique is a powerful tool to reveal an
interaction between the 15N-labeled protein and the unla-
beled ligand and shows which residues of the protein are
involved in the binding. Therefore 1H, 15N assignment of
protein resonances is a prerequisite. A two dimensional
(2D) 1H-15N HSQC (Heteronuclear Single Quantum
Docking experiments result in 5 families for pamoic acid conformations in the 8 kDa domainFigure 2
Docking experiments result in 5 families for pamoic acid conformations in the 8 kDa domain. The five main con-
formations of pamoic acid generated by docking experiments are shown against on the electrostatic surface of the 8 kDa 
domain generated by Pymol. The positively charged surface is colored in blue and the negatively one is colored in red. The ori-
entation is the same as in Figure 1. The best final docked energy calculated by AutoDock appears for each family of conforma-
tions. Pictures were prepared with PyMOL [48].Page 4 of 12
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domain, corresponding to the first 87 amino-acid residues
of pol beta, was recorded. Protein 1H and 15N resonances
were assigned using TOCSY-HSQC and NOESY-HSQC
based strategies and confirmed NMR data previously
reported for the 8 kDa domain [30]. A satisfactory agree-
ment of HSQC spectra with the reported data insured that
the protein is well-folded [31,32].
A series of 2D 1H-15N HSQC spectra was monitored upon
addition of pamoic acid. As the spectra could be easily
superimposed, we concluded that the structure of the 8
kDa domain is not altered upon ligand addition. Chemi-
cal shifts of the crosspeaks have been followed during
titration (Fig. 3a). The peak positions changed between
those characteristic of the free and bound forms, indicat-
ing fast exchange on the NMR chemical shift timescale.
Comparison of the two spectra recorded for the protein in
its free state and in the presence of a 4-fold molar excess
of pamoic acid revealed a small number of amino-acids
that are affected upon ligand binding. The chemical shift
Chemical Shift Perturbation analysis of the 8 kDa domain upon pamoic acid bindingFigure 3
Chemical Shift Perturbation analysis of the 8 kDa domain upon pamoic acid binding. a. Superposition of 2D 15N-1 
H HSQC spectra of the 15N-labeled 8 kDa domain recorded without (green peaks) and with (red peaks) a 4-fold molar excess 
of pamoic acid. The four most perturbed residues crosspeaks are annotated. b. Histogram of chemical shift variation D upon 
binding to pamoic acid. Ala42, Gly64, Gly66 and Ile69, which showed a significant D value, higher than 3-times the standard 
deviation, are indicated. c. Mapping of the four residues Ala42, Gly64, Gly66 and Ile69 on the structure of the 8 kDa domain. 
Sidechains of amino-acids shown by Chemical Shift Mapping to be involved in the interaction are colored in magenta. The ori-
entation of the molecule is the same as that in Figure 1. The picture was prepared with PyMOL [48].Page 5 of 12
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section) of the same crosspeak between the free and the
ligand bound state were plotted versus the pol beta residue
numbers (Fig. 3b). Amide groups of Ala42, Gly64, Gly66
and Ile69 showed a significant D value (≥ 3 × standard
deviation), indicating that these amino-acids belong to
the binding site of pamoic acid. Previous studies reported
that Lys35, Tyr39, Arg83 and Leu85 were also affected by
binding [26]. To characterize binding, we used a thresh-
old for D value equal to 3 × standard deviation instead of
1.5 as in the paper [26]. With the multiplier set to 1.5,
Lys35, Arg83 and Leu85 were also found to be affected by
binding in our experiments. Interestingly, chemical shift
mapping at higher protein concentration revealed that
Lys35, Tyr39, Arg83 and Leu85 were also affected by bind-
ing (data not shown). However, Arg83 and Leu85 are
located far from the other affected residues, on an unstruc-
tured loop, which is a part of an alpha helix in the entire
39 kD protein. These residues are therefore unlikely to be
involved in the binding of pamoic acid to the entire pro-
tein.
Furthermore, comparing the results of the in silico docking
with those obtained from chemical shift mapping showed
a good agreement. All retained docked structures are
located in the site revealed by Chemical Shift Mapping
experiments, the one which corresponds to the single-
stranded DNA binding. Among the five conformations
proposed by AutoDock, conformation n°5 could be
rejected as it was not close enough to Gly64 and Gly66,
which have been shown to be involved in pamoic acid
binding. Therefore, at this step, four conformations were
retained.
A NOE correlation helps in determining the correct 
conformation
In order to further discriminate the right position, we
looked for intermolecular NOEs. 3D 15N-TOCSY-HSQC
(TOtal Correlated SpectroscopY) and 3D 15N-NOESY-
HSQC (Nuclear Overhauser Enhancement SpectroscopY)
spectra of the free 15N-labeled 8 kDa domain were
acquired and 3D 15N-NOESY-HSQC spectrum was
recorded in the presence of equimolar pamoic acid con-
centration.
Pamoic acid protons (Fig. 4a) have been assigned in a
straightforward manner using COSY-DQF, TOCSY and
NOESY experiments (data not shown). Careful analysis of
both spectra revealed the presence of an intermolecular
NOE correlation peak. The chemical shifts of this NOE
corresponded to the amide proton of Ile69 and to the pro-
ton Ha of pamoic acid, indicating that these protons are
located within 6 Å from each other (Fig. 4b).
The atomic contacts were computed from the four
retained structures by assuming that the maximal distance
between a pair of protein-ligand atoms does not exceed 6
Å. Among these distances we selected the ones corre-
sponding to the amide proton of Ile69 and the two Ha
protons of pamoic acid. The 55 best structures that ful-
filled this condition were visually inspected and showed
that three different conformations were admissible. More
than half of the 55 structures corresponded to conforma-
tion n°1 depicted on Fig. 2a. The two other conforma-
tions represented 30% (conformation n°2, Fig. 2b) and
18% (conformation n°3, Fig. 2c) of the full AutoDock
structure set.
Two important protons for the interaction between the 8 
kDa domain and pamoic acid
In order to get further structural information on the bind-
ing, Saturation Transfer Difference (STD) experiments
were carried out. The principle of this technique is to
transfer the saturation from the protein to the bound lig-
and [33]. Protein protons that are shifted outside of the
spectral window of low molecular weight compounds are
selectively irradiated. Within a short time, the saturation
is spread over the entire 8 kDa domain through spin dif-
fusion. The spin diffusion is more efficient when the
molecular mobility is restricted, which is the case for large
molecules like proteins. The spin diffusion may also occur
between a protein and its ligand, assuming they are close
enough. The closer the distance from the binding site, the
larger the saturation, indicating the ligand's binding
epitope [34].
We performed STD experiments with the 8 kDa domain at
5 µM and pamoic acid in a 20-fold molar excess. Two
pamoic acid protons were found to carry most of the sat-
uration, namely Hd and He (Fig. 4a and 5a), indicating a
close proximity with the 8 kDa domain. However, He car-
ried a larger saturation, indicating a closer contact with the
8 kDa domain than Hd [34]. This structural information
was used to select the correct conformation of the bound
pamoic acid among the three remaining ones.
Searching through the computed atomic contacts, we ana-
lyzed the distances between Hd or He and protein atoms
and found that two of the three remaining conformations
did not feature sufficiently close contacts to give rise to
STD signals, namely conformations n°1 and n°3. Moreo-
ver, ligand protons that are closer to the protein than Hd
and He in these conformations did not give STD signals.
By contrast, every structure in conformation n°2 family
showed at least one distance below 2,6 Å between these
two protons of pamoic acid and one of the protein pro-
tons.Page 6 of 12
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ligand has been added gradually up to around a 50-fold
molar excess with respect to the protein concentration. As
STD technique requires low concentrations in ligand and
protein, it is less affected by interferences due to addi-
tional non-specific binding visible in Kd measurements
[35]. STD amplification factor was plotted versus the lig-
and excess. Assuming a stoichiometric complex, fitting the
curve of the STD amplification factor of the major proton
He provided the Kd value of 13 µM ± 5 µM (Fig. 5b) [34].
Model of the interaction between the pamoic acid and the 
8 kDa domain
In the final stage of the analysis, conformation n°2 was
retained to establish the model of the complex between
the 8 kDa domain and pamoic acid, since it complied
with all the NMR data. This structural set of AutoDock
results represents an experimentally validated and unique
strutural model for the complex 8 kDa domain – pamoic
acid (Fig. 6).
Under these assumptions, we analysed the contacts
between the validated ligand structure and the 8 kDa
domain atoms. The aromatic groups of pamoic acid prob-
ably form favorable hydrophobic interactions with the
main amino-acids of the site, such as Tyr39, Ala42, Gly64
and Gly66. Amide protons of Gly64 and Gly66 are
shielded upon pamoic acid addition. This can be corre-
lated with the fact that both residues are affected by mag-
netic anisotropy of the naphtalene nucleus [36].
Furthermore, numerous lysine residues present in the site
can form electrostatic interactions with both carboxyl
groups. One of the carboxyl groups is oriented towards
His34 and Lys35. It makes close contacts with Ile69 amide
proton and electrostatic interaction with the terminal
A NOE correlation indicates a distance lower than 6 Angströms between the Ha proton of pamoic acid and the amide proton of the 8 kDa domain Ile69Figure 4
A NOE correlation indicates a distance lower than 6 Angströms between the Ha proton of pamoic acid and 
the amide proton of the 8 kDa domain Ile69. a. Structure of pamoic acid with proton symbols, as used in the text. b. 
Two strips of 3D NOESY-HSQC spectrum corresponding to the Ile69 amide proton. The first strip was recorded without 
pamoic acid and the second in the presence of equimolar pamoic acid concentration. On the second strip, an additional cross-
peak, orange-framed, appeared at 8,65 ppm. This crosspeak revealed an intermolecular NOE between the Ha pamoic acid pro-
ton and the amide proton of the 8 kDa domain Ile69.
b.a.Page 7 of 12
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group forms hydrogen bonds with the amide proton of
Lys68 (distance of 1,67 Å) and with the hydroxyl group of
Thr67 (distance of 1,94 Å). Obviously, the two carboxyl
groups contribute to pamoic acid affinity for the 8 kDa
domain. Using one of them to tether a second fragment is
likely to lower the affinity but this may be compensated
by the properties of the second fragment. From our data,
we have defined two other potential sites close to the
pamoic acid binding site (see above). In the proposed
model, each of the carboxyl groups is oriented towards
one of the other sites. Therefore the possibility of increas-
ing the pamoic acid affinity by using the fragment-based
approach could be considered.
Conclusion
Pol beta gets involved in DNA repair pathway and in
translesion synthesis, particularly when it is overexpressed
in cancer cell lines treated by cisplatin agent. This process
leads to a chemotherapeutic drug resistance, which could
be prevented by an adjuvant treatment, that is to say a pol
beta inhibitor. One of the key benchmarks for a small
molecule to become a drug is the affinity for its target. No
currently known pol beta inhibitors rise above micromo-
lar affinity, which is insufficient for any pharmacological
development. The X family DNA polymerases is the only
one to feature the 8 kDa domain [37]. Hence, an inhibitor
of this domain is less subject to bind to replicative DNA
polymerases. Moreover, inhibition of the 8 kDa of pol
lambda and pol mu, both involved in non-homologous
end joining of DNA break [38,39], could improve the
radiosensitivity of tumors by preventing cells from repair-
ing radiotherapy-induced DNA damage.
Even if pamoic acid is one of the most known pol beta
specific inhibitors, its affinity (low micromolar) has to be
improved. Structural insights in the interaction between 8
kDa domain of pol beta and pamoic acid are prerequisites
to improve the ligand affinity by applying the fragment-
based strategy.
A previous work has reported the binding of pamoic acid
to pol beta using chemical shift mapping. Pamoic acid is
one of the best known pol beta specific inhibitors. It
inhibits the deoxyribose phosphate lyase activity and
increases sensibility to MMS [26]. As pol beta has been
NH3
+
Saturation Transfer Difference experiments reveal that two pamoic acid protons are essential in the binding to the 8 kDa domainFigure 5
Saturation Transfer Difference experiments reveal that two pamoic acid protons are essential in the binding 
to the 8 kDa domain. a. Superposition of STD spectra, without (in blue) and with (in red) selective saturation of the 8 kDa 
domain protons. Only Hd and He pamoic acid protons revealed binding to the 8 kDa domain. b. Plot showing STD amplifica-
tion factor of He versus pamoic acid concentration. Fitted curve is represented in red, corresponding to Kd value of 13 µM ± 5 µM.Page 8 of 12
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affinity of pamoic acid for pol beta could transform pam-
oic acid into a drug-candidate. In the present paper, we
have combined NMR (chemical shift mapping, STD and
NOESY data) and computational approaches to generate
a detailed 3D model of the complex of the 8 kDa domain
of the DNA polymerase with pamoic acid. Validation of
the computational model by experimental NMR data gave
a unique structure for the complex (Fig. 6). The site occu-
pied by pamoic acid corresponds to the one where single-
stranded DNA binds to.
Indeed, the model thus established is the starting point to
search for a fragment that could bind in one of the other
two sites found in the vicinity of the pamoic acid binding
site. The orientation of its bound carboxyl groups towards
two distinct potential second sites makes pamoic acid a
very interesting candidate for further attempts to increase
its affinity for pol beta, using fragment-based approach.
Furthermore, as NMR techniques can screen small mole-
cules, they can be used to find a second fragment which
binds to the 8 kDa domain in a site, which is close to but
disjointed from the pamoic acid binding site [40]. The
present structure of the complex opens an avenue for the
development of new families of specific pol beta inhibi-
tors by the well-established fragment based approach.
Glu26 or Lys72. Another potential second site could be
related to Lys60, Leu62 and Ala70, further in the direction
of Gly64 and Gly66, which belong to the pamoic acid site.
be reported elsewhere.
Methods
Protein expression and purification
For NMR experiments, the recombinant 8 kDa-domain of
DNA polymerase beta (Met1-Lys87) was produced as His-
tag fusion protein in a pET28 plasmid (Novagen) in E. coli
BL21(DE3). Bacteria were grown in LB medium at 37°C
to an optical density at 600 nm of 0.8 before induction
with 1 mM IPTG during 4 hours, to obtain an unlabeled
sample. Isotopically 15N-labeled protein was expressed in
minimal (M9) medium containing 15NH4Cl. Proteins
were purified using a Ni-NTA column (HiTrap, Amer-
3D model of the 3D structure of the 8 kDa domain – pamoic acid complex validated by NMR dataFigure 6
3D model of the 3D structure of the 8 kDa domain – pamoic acid complex validated by NMR data. a. Electro-
static surface of the 8 kDa domain, with the same orientation as that in Figure 1, illustrating the cavity with the pamoic acid 
binding site. Blue-colored surface represents positively charged residues and red-colored surface represents the negative ones. 
Carbon atoms of pamoic acid are colored in cyan and oxygen atoms are colored in red. b. Detailed view of the interaction 
illustrating the binding of pamoic acid to the 8 kDa domain in its experimentally validated conformation. The distances that 
allowed the identification of the right conformation are shown. The distance between the amide proton of Ile69 and the pam-
oic acid Ha proton is 2,27 Å. He and Hd are located at 3,12 Å of Ala42 amide proton and at 4,25 Å of Gly64 HA proton, 
respectively. The pictures were prepared with PyMOL [48].Page 9 of 12
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500 mM in 5 column volumes, after 8 column volumes at
imidazole 100 mM. The protein was eluted at imidazole
250 mM. The protein was then concentrated to 0.5–2 mM
in 20 mM deuterated Tris-HCl, pH = 6.8, 200 mM NaCl.
The His-tag was cleaved using one unit of thrombin per
milligram of protein overnight at 4°C (Novagen).
Pamoic acid preparation
Pamoic acid was obtained from Sigma-Aldrich. It was dis-
solved in high-pH Tris-HCl 20 mM, 200 mM NaCl at a
concentration of 10 mM. Then, the pH was brought down
to 6.9 by addition of the appropriate volume of HCl. The
final solution was stored at 4°C.
NMR spectroscopy
NMR spectra were recorded at 293 K on a Bruker DRX600
spectrometer equipped with a cryoprobe. NMR samples
were prepared in 20 mM deuterated Tris-HCl, pH = 6.8,
200 mM NaCl with 10% D2O. NMR data were processed
using TOPSPIN software (Bruker) and NMRPipe [41] and
analyzed using NMRView [42]. Resonance assignment
was performed using previously reported BMRB data
[43,44] and 3D TOCSY-HSQC and 3D NOESY-HSQC
data. Spectra were recorded on the free 15N-labeled 8 kDa
domain at 500 µM and on the equimolar complex with
1024, 80 and 128 complex points for 1H, 15N and 1H
respectively, and 8 scans. The mixing time for TOCSY and
NOESY were 60 ms and 200 ms, respectively.
NMR chemical shift mapping
For NMR titration, 2D 15N-HSQC spectra of the 15N-
labeled 8 kDa domain of pol beta at the concentration of
150 µM were collected at 293 K after incremental addition
of pamoic acid (typically 0.25, 0.5, 1, 1.5, 2, 3, 4 molar
equivalents of ligand) with 2048 and 256 complex points
for 1H and 15N, respectively, and 4 scans. The NMR sam-
ple was diluted by no more than 10% by increasing the
pamoic acid concentration.
As the pamoic acid is in fast exchange rate between the
free and bound states compared with the chemical shift
difference, the observed signal is at a chemical shift corre-
sponding to the weighted average between the chemical
shifts of the free and bound states. For each residue, the
chemical shift difference was calculated as :
The factor of 5 appearing for ∆δ N corresponds to the
spectral widths ratio of 15N (25 ppm) and 1H (5 ppm) and
is commonly used in the literature [45].
Saturation Transfer Difference experiments
For STD titration, a sample of 3 µM of unlabeled protein
in deuterated buffer was prepared. Increasing amounts of
pamoic acid were added, in molar ligand/protein excess
from 1 to 30.
Protein signals were saturated by forty 50 ms gaussian
pulses, with interpulse spacing of 1 ms. The total satura-
tion time was 2 s. Water signal elimination was performed
using Watergate W5 sequence [46]. Protein signals were
eliminated by a 60 ms T1ρ filter with a 5000 Hz excita-
tion. For each ligand concentration, two spectra were
recorded with and without protein irradiation. For I0 spec-
trum, no irradiation of the protein occurred. I std spec-
trum is obtained by substraction of spectrum with protein
irradiation from the I0 spectrum.
For each ligand proton signal, STD amplification factor is
calculated as follow :
where I0 and Isat are the signal intensity of a ligand proton
in the spectra without and with protein irradiation,
respectively. The dissociation constant was obtained from
least-squares fitting of Amax as a function of total ligand
concentration according to the following equation :
[L] represent pamoic acid concentration. Kd and Amax were
searched parameters in fitting using the GOSA program
[47].
Docking experiments
The protein-ligand docking was performed using the
AutoDock 3.05 software [27]. The input files were pre-
pared with the MGLTools 1.2. A pdbqs file was created,
based on PDB: 1DK3 file information. Polar hydrogens
were added and charges were calculated. From these data,
a grid map of 96 × 126 × 96 points with a distance spacing
of 0.442 Angströms representing the three-dimensional
protein structure was calculated and used for the docking.
The appropriate atom-specific affinity maps were created.
The grid map covered the entire protein structure so that
the ligand could move freely within the grid around the
protein. For the ligand, pamoic acid, flexible docking has
been enabled by defining 8 rotatable bonds within the
molecule. The search of the parameter space followed the
Lamarckian genetic algorithm, with most of the user-
defined parameters set to their default values. We modi-
fied the population size by setting it to 1000 individuals,
as well as the number of surviving individuals, the maxi-
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number of generations, which were multiplied by 10 with
respect to their default values. With the number of gener-
ated structures set to 256, a typical run averaged 6 hours
on a single Xeon 3 GHz CPU. Run in parallel on a 40-
nodes Linux cluster, with different seeds for random
number generator, the above setup allowed obtaining
10240 ligand conformations each time the program was
launched. The results have been analyzed with an in-
house software, allowing the analysis of the intermolecu-
lar energy and atomic contacts.
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